Article Information
History
- May 26, 2017.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Wael Bahnan1,
- Justin C. Boucher1,
- Petoria Gayle1,
- Niraj Shrestha1,
- Mark Rosen2,
- Bertal Aktas3,
- Becky Adkins1,
- Arba Ager1,
- Wasif N. Khan1 and
- Kurt Schesser1⇑
- 1Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, Florida;
- 2Janssen Research & Development, San Diego, California;
- 3Hematology Laboratory for Translational Research, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
- To whom correspondence should be addressed:
Kurt Schesser, Dept. of Microbiology & Immunology, University of Miami Miller School of Medicine, 1600 NW 10th Ave, Miami, Florida 33136. Telephone: (305) 243-4760; kschesser{at}med.miami.edu; Wasif N. Khan, Dept. of Microbiol. & Immunol., University of Miami Miller School of Medicine, 1600 NW 10th Ave, Miami, Florida 33136. Telephone: (305) 243-5694; wnkhan{at}med.miami.edu
Posted May 26, 2017.
The eIF2α kinase Heme Regulated Inhibitor (HRI) protects the host from infection by regulating intracellular pathogen trafficking
